Helix Acquisition CORP Ii
Market Movers (8-K)
BridgeBio Oncology Therapeutics reports Q1 2026 financial results, highlights progress in three RAS-pathway inhibitor programs, and anticipates clinical readouts in H2 2026 with cash runway into 2028.
BridgeBio Oncology Therapeutics, Inc. announced the appointment of Peter Lebowitz, M.D., Ph.D. to its Board of Directors, expanding the board to nine members.
BridgeBio Oncology Therapeutics announced its full year 2025 financial results and positive clinical data across its three RAS-pathway inhibitor programs, extending its cash runway into 2028.
Better than expected
BridgeBio Oncology Therapeutics announced positive preliminary safety and antitumor data across three innovative RAS and PI3Ka pipeline programs.
Better than expected
BridgeBio Oncology Therapeutics, Inc. announced its third-quarter 2025 financial results, highlighting pipeline progress and a strong cash position extending into 2028.
Capital raise
Worse than expected
BridgeBio Oncology Therapeutics, Inc. (BBOT) has successfully completed its business combination with Helix Acquisition Corp. II, debuting on the Nasdaq Global Market with approximately $382 million in gross proceeds.
Better than expected
Capital raise
Quarterly Earnings (10-Q)
BridgeBio Oncology Therapeutics reported a net loss of $42.1 million for Q1 2026, with increased R&D expenses driven by clinical trial activities.
Capital raise
Worse than expected
BridgeBio Oncology Therapeutics reports significant cash increase and expanded R&D post-de-SPAC transaction, while net losses widened due to increased operational and clinical development costs.
Worse than expected
Capital raise
Helix Acquisition Corp. II reports significant progress on its proposed business combination with BridgeBio Oncology Therapeutics, securing substantial PIPE investments and non-redemption agreements, despite facing a current liquidity deficit and a going concern warning.
Capital raise
Worse than expected
Helix Acquisition Corp. II reports a net loss for Q1 2025 as it progresses towards a proposed business combination with BridgeBio Oncology Therapeutics.
Capital raise
Worse than expected
Helix Acquisition Corp. II, a special purpose acquisition company, reported a net income of $2.3 million for the quarter ended September 30, 2024, primarily driven by interest income from its trust account.
Better than expected
Capital raise
Helix Acquisition Corp. II reported a net income of $2.2 million for the quarter ended June 30, 2024, primarily driven by interest earned on marketable securities held in trust.
Capital raise
Annual Reports (10-K)
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported encouraging early clinical data for its oncology pipeline and completed a significant de-SPAC transaction, bolstering its financial position for future development.
Capital raise
Better than expected
Helix Acquisition Corp. II details its outstanding Class A and Class B ordinary shares, preference shares, and related shareholder rights in its annual 10-K filing.
Capital raise
Insider Trading (Form 4)
Marc Cobo, Principal Accounting Officer at BridgeBio Oncology Therapeutics, Inc., reported a transaction involving the withholding of shares for tax obligations.
BridgeBio Oncology Therapeutics COO & Principal Financial Officer Idan Elmelech sold 343 shares of common stock for $7.80 per share to cover tax obligations.
BridgeBio Oncology Therapeutics reports a Form 4 filing detailing the acquisition of common stock by Chief Medical & Development Officer Ben Yong, with shares withheld for tax obligations.
BridgeBio Oncology Therapeutics reports a transaction involving President and CEO Pedro Beltran, who had shares withheld for tax obligations.
Bihua Chen reports changes in beneficial ownership of BridgeBio Oncology Therapeutics, Inc. (BBOT) common stock, detailing distributions and indirect holdings.
Praveen Tipirneni, a Director at BridgeBio Oncology Therapeutics, Inc., has reported the acquisition of stock options.
Proxy Statements (Def-14A)
BridgeBio Oncology Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors and ratify auditor appointments.
New Public Companies (S-1)
BridgeBio Oncology Therapeutics, Inc. (BBOT) filed an S-1 registration statement detailing its recent SPAC merger, PIPE financing, and clinical-stage oncology pipeline targeting RAS and PI3K-driven cancers.
Delay expected
Worse than expected
Capital raise
Helix Acquisition Corp. II files a registration statement to offer an additional 1,150,000 Class A ordinary shares.
Capital raise
Helix Acquisition Corp. II, a blank check company, aims to raise $150 million through an initial public offering to pursue a business combination within the healthcare industry.
Capital raise
Helix Acquisition Corp. II, a blank check company, is set to launch a $150 million IPO targeting the healthcare industry.
Capital raise
Helix Acquisition Corp. II, a blank check company affiliated with Cormorant Asset Management, aims to raise $100 million in an initial public offering to pursue a business combination within the healthcare sector.
Capital raise
Schedule 13D - Activist Investments
BridgeBio Oncology Therapeutics, Inc. reports a pro rata distribution of shares by Helix Holdings II LLC to its members, impacting ownership percentages.
BridgeBio Pharma LLC and BridgeBio Pharma, Inc. have acquired a 17.5% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc. following a business combination.
BridgeBio Oncology Therapeutics, formerly Helix Acquisition Corp. II, completed its business combination with TheRas, Inc., leading to significant shareholding changes for key investors including Bihua Chen.
Capital raise
SCHEDULE 13D/A: Helix Acquisition Corp. II Announces Definitive Business Combination with BridgeBio Oncology Therapeutics, Securing $260M PIPE Investment
Helix Acquisition Corp. II has entered into a definitive business combination agreement with BridgeBio Oncology Therapeutics, Inc., which includes a $260 million PIPE investment and a planned domestication to Delaware.
Capital raise
Schedule 13G - Passive Investments
Citadel entities and Kenneth Griffin report a 3.2% beneficial ownership in BridgeBio Oncology Therapeutics, Inc. Class A ordinary shares.
Adage Capital Management and its principals have filed an amended Schedule 13G, reporting a 1.88% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc.
BC Global Opportunities IX LP and affiliated entities have disclosed a 5.51% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc. common stock.
Deerfield Management and affiliated funds have disclosed a passive 6.17% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc. common stock.
Millennium Management and related entities have disclosed beneficial ownership of up to 4.7% of Helix Acquisition Corp. II's Class A Ordinary Shares.
Sculptor Capital LP and its affiliates have reported a beneficial ownership of 5.12% in Helix Acquisition Corp II's Class A Ordinary Shares, totaling 967,460 shares.